Heike Keilhack

Company: Ribon Therapeutics

Job title: CSO

Seminars:

Targeting Cellular Stress Response in Dermatology – the Emergence of PARP14 as a Novel Drug Target to Treat Th2/Th17-Mediated Inflammation 3:10 pm

PARPs or ARTs are stress-induced enzymes, and their cellular function can get corrupted in disease Evolution of PARP14 as a promising target in Atopic Dermatitis with differentiated MOA RBN-3143, a clinical-stage PARP14 inhibitor, is an oral alternative to biologics foe a target that shows restricted expression in inflammatory lesionsRead more

day: Day One Translational Track PM